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The role of prolactin on breast cancer development and progression is debated. Breast 
cancer progression largely depends on cell movement and on the ability to remodel 
the actin cytoskeleton. In this process, actin-binding proteins are requested to achieve 
fibrillar actin de-polymerization and relocation at the cell membrane. Kinases such as 
focal adhesion kinase (FAK) are later required to form actin/vinculin-enriched structures 
called focal adhesion complexes, which mediate firm adhesion to the extracellular matrix. 
These controllers are regulated by c-Src, which forms multiprotein signaling complexes 
with membrane receptors and is regulated by a number of hormones, including pr olactin. 
We here show that breast cancer cells exposed to prolactin display an elevated c-Src 
expression and phosphorylation. In parallel, increased moesin and FAK expression 
and phosphorylation are found. These molecular changes are associated to relocation 
to the plasma membrane of cytoskeletal actin fibers and to increased horizontal cell 
movement. In conclusion, prolactin regulates actin remodeling and enhances breast 
cancer cell movement. This finding broadens the understanding of prolactin actions on 
breast cancer cells, highlighting new pathways that may be relevant to on breast cancer 
progression.
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inTrODUcTiOn
In the recent past, prolactin (PRL) has been recognized to have broader actions than previously 
thought. While first identified as the key hormone mediating growth and differentiation of mam-
mary epithelium and lactation, PRL has recently gained attention for its role in the development 
of breast cancer (1, 2). PRL effects on breast cancer are mediated by interaction with its receptor 
(PRLR), a member of the cytokine receptor superfamily, characterized by a tripartite structure: an 
extracellular ligand-binding domain, a short transmembrane domain, and an intracellular domain. 
PRLR signaling is triggered by the contemporary interaction of PRL with two receptors: a high affin-
ity PRL site binds one receptor, and a lower affinity PRL site binds another receptor, thus favoring 
the formation of a ternary complex comprised of PRL and two PRLR (3).
High PRL levels are directly linked with breast cancer risk (4) and with worse prognosis in breast 
cancer patients (5). Transgenic rodents overexpressing PRLR in the breast develop mammary tumors 
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with a high frequency (6). PRL also antagonizes cytotoxicity by 
chemotherapeutic agents, thus reducing the efficacy of available 
treatments (2).
Prolactin receptor is found in up to 80% of breast cancer cells 
(7), where it couples to several signaling pathways, including Janus 
Kinase (JAK)-2/Signal Transducer and Activator of Transcription 
(STAT)-5, mitogen-activated protein kinase (MAPK), and 
phosphatidylinositol-3-OH-kinase (PI3K). Activation of these 
pathways directly impacts proliferation, survival, and cytoskeletal 
dynamics, thus influencing initiation and progression of mam-
mary tumors (1). On these grounds, PRLR is currently being 
exploited as a potential therapeutic target in breast cancer (3).
Activation of MAPK and PI3K is an established mechanism 
through which sex steroid hormones modulate the architecture of 
the cytoskeleton in breast cancer cells (8). The actin cytoskeleton 
forms the backbone of the cell, and its spatial organization is crucial 
for cell movement. Modification of the intracellular localization 
of actin fibers and of their interaction with membrane-anchoring 
structures, such as integrins and focal adhesion complexes, allows 
cell movement in the extracellular environment and is directly 
linked to the ability to achieve local and distant metastasis (9).
Prolactin is able to recruit signaling intermediates such as 
c-Src that are upstream controllers of PI3K and focal adhesion 
kinase (FAK) in breast cancer cells (10). Activation of PI3K by 
PRL results from either direct binding to PRLR or from Src acti-
vation (1). This is remarkably similar to the regulatory actions of 
estrogen receptor alpha (ER alpha) (11), that is, an established 
modulator of the actin cytoskeleton in breast cancer cells through 
the recruitment of c-Src-mediated signaling to actin-regulatory 
proteins and FAK (8).
It is currently unclear whether PRL/PRLR signaling may turn 
into modifications that have an impact on breast cancer cell 
movement and possibly metastasis through the control of actin 
cytoskeleton rearrangement. The aim of this work has been to 
explore this possibility, through the analysis of breast cancer cell 
horizontal movement during exposure to PRL, through the study 
of the cytoskeletal modifications induced in these cells by PRL, 
and by a preliminary characterization of the molecular pathways 
involved.
MaTerials anD MeThODs
cell culture and Treatments
T47D (ATCC®HTB-133™), ZR75-1 (ATCC®CRL-1500™), 
and MCF-7 (ATCC®HTB-22™) human breast cancer cells were 
obtained from the American Tissue Culture Collection (ATCC®, 
Manassas, VA, USA) and cultured as previously described 
(12). T47D and ZR75-1 cells were maintained in Roswell Park 
Memorial Institute 1640 Medium (1X) (RPMI). MCF-7 cells 
were maintained in Dulbecco’s Modified Eagles’s Medium 
(DMEM). The culture mediums were supplemented with 10% of 
fetal bovine serum (FBS), 1.2% of l-glutamine, 1.2% of penicil-
lin, 1.2% of [4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic 
acid (HEPES), 1.2% of pyruvate, 2.4% of sodium bicarbonate, 
and 0.24% of insulin. The cells were plated in different dishes 
(six well, 35  mm diameter) at a density of 2  ×  104 cells/ml 
(2 ml of RPMI or DMEM), at a 37°C in 5% CO2. The mediums 
and the FBS were purchased from Gibco (Grand Island, NY, 
USA). All others reagents were purchased from Sigma-Aldrich 
(Gillingham, England). Before treatments, the cells were kept for 
48 h in culture medium containing FBS deprived of steroids with 
charcoal stripping. Before experiments, the cells were kept for 8 h 
in culture medium containing no FBS. We treated the cells with 
three different doses of PRL: 25, 50, and 100 ng/ml, as previously 
described (10). Prolactin was purchased from Abnova (P4122, 
Human Recombinant Protein, Taiwan).
gene silencing with sirna and 
Transfection experiment
To transfect anti-hPRLRsiRNA (AM16708-ID106337, ambiom®, 
ThermoFisher Scientific, Grand Island, NY, USA), cells were 
plated at 70% confluence in six-well dishes. After 12 h, cells were 
transfected with siRNA using Lipofectamine 2000 Transfection 
Reagent (ThermoFisher Scientific, Grand Island, NY, USA) 
according to the manufacturer’s instructions. Briefly, siRNA was 
diluted at a concentration of 30 nM in culture medium, in a final 
volume of 100 μl, mixed by vortexing, and then 6 μl lipofectamine 
was added to the diluted siRNA. The samples were mixed by 
pipetting and incubated for 20 min at room temperature. Then, 
the transfection complex was added to 2  ml medium without 
antibiotics. After 6 h, when the transfection occurred, new cell 
growth medium containing serum and antibiotics was added 
to the cells. Cells were incubated with the transfection complex 
under their normal growth conditions and monitored for gene 
silencing after 48 h (13).
cell-Migration assays
Cell migration was assayed with razor-scrape assays as previ-
ously described (14). Briefly, a razor blade was pressed trough 
the confluent T47D, ZR75-1, and MCF-7 monolayer into the 
plastic plate to mark the starting line. T47D, ZR75-1, and MCF-7 
were swept away on one side of that line. Cells were washed, 
and 2.0 ml of RPMI (T47-D and ZR75-1) and DMEM (MCF-7) 
containing steroid-deprived FBS were added. Cytosine β-d-
arabinofuranoside hydrochloride (Sigma-Aldrich, Gillingham, 
England) (10 μM) was used 1 h before the hormone was added. 
Migration was monitored for 48  h (15, 16). Every 12  h, fresh 
medium and treatment were replaced. Cells were digitally 
imaged and migration distance in micrometer was measured with 
phase-contrast microscopy (Axiolab Standart 2.0 Carl Zeiss, Jena, 
Germany).
cell immunofluorescence
After exposure to 30  min of treatment with PRL, cells were 
fixed with 4% paraformaldehyde for 30 min and permeabilized 
with 0.1% Triton for 5  min. Blocking was performed with 3% 
normal serum for 30 min. Cells were incubated with Texas red-
linked antibody against Phalloidin (Sigma-Aldrich, Gillingham, 
England). The nuclei were counterstained with 4′,6-diamidino-
2-phenylindole (DAPI) (Sigma-Aldrich, Gillingham, England). 
Immunofluorescence was visualized using an Olympus BX41 
microscope and recorded with a high-resolution DP70 Olympus 
FigUre 1 | (a) Migration of T47D cells 48 h after administration of different PRL doses (nanogram per milliliter) with or without anti-hPRLR siRNA. Images were 
converted into a spectrum of grays. The arrow points to the direction of migration. The upper black line is where migration begins, and the lower black line shows 
the maximal migration distance. The distance covered by the migrating cells was measured in micrometers. *p < 0.05 vs. control. The representative images show 
T47D (a), MCF-7 (B), and ZR75-1 (c) migration. Each experiment was repeated three times. (D) shows PRLR expression after different PRL doses (nanogram per 
milliliter) in the presence or absence of anti-hPRLR siRNA. PRLR densitometry value was adjusted for GAPDH and then normalized to control (Con). The experiment 
was repeated four times. *p < 0.05 versus control.
December 2015 | Volume 6 | Article 1863
da Silva et al. Prolactin Promotes Breast Cancer Migration
Frontiers in Endocrinology | www.frontiersin.org
digital camera. After conversion to gray scale images, the cell 
membrane thickness and the gray levels of the extracellular area, 
cell membrane, as well as cytoplasm were quantified, as previously 
described (17) using the LeicaQWin image analysis and image 
processing software (Leica Microsystems, Wetzlar, Germany). We 
analyzed, in 50 cells per condition, an area of 40 pixel-distance 
encompassing the extracellular space, the full thickness of the 
membrane and the intracellular space. Five separate measures 
were taken in each cell.
immunoblottings
Cell lysates were separated by sodium dodecyl sulphate (SDS) poly-
acrylamide gel electrophoresis (PAGE). Primary antibodies used 
were: PRLR (D01PID5618, Abnova, Taiwan); Moesin (SC6410, 
Santa Cruz, Texas, USA); p-Moesin (SC12895, Santa  Cruz, 
Texas, USA); FAK (SC271195, Santa Cruz, Texas, USA); p-FAK 
(SC11765-R, Santa Cruz, Texas, USA); c-Src (SC5266, Santa 
Cruz, Texas, USA); p-c-Src (SC166860, Santa Cruz, Texas, USA); 
GAPDH (SC59540, Santa Cruz, Texas, USA). The secondary anti-
bodies Anti-rabbit (SC2357, Santa Cruz, Texas, USA) (1:3000) for 
PRLR; Anti-goat (SC2768, Santa Cruz, Texas, USA) (1:3000) for 
Moesin, p-Moesin and Actin, and Anti-Mouse (SC2005, Santa 
Cruz, Texas, USA (1:3500) for FAK, p-FAK, c-Src, p-c-Src, and 
GAPDH were incubated for 2 h in room temperature. Primary 
and secondary antibodies were incubated with the membranes, 
followed by three 5-min washings with TRIS-buffered saline-
Tween 20. Immunodetection was carried out using enhanced 
chemiluminescence and was recorded with a quantitative digital 
imaging system (Quantity One, BioRad, Hercules, CA, USA), 
enabling us to assess saturation. Band densitometric analysis was 
FigUre 2 | (a) The box on top of the cells display sample areas of measurement (one per cell, indicated as the yellow area). (B) shows T47D cellular actin stained 
with phalloidin linked to Texas Red (red staining) upon administration of different PRL concentrations (nanogram per milliliter). Nuclei were counterstained with DAPI 
(blue staining). (c) shows the mean thickness of the plasma membrane. Measurements were made in 50 different cells per condition with 5 different membrane 
thickness measurements per each cell. The experiment was carried out three times. *p < 0.05 in vs. control.
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quantified, as previously described (17), with the ImageJ image 
program (National Institute of Health – NIH, USA) using condi-
tions ensuring analysis in the linear range of detection.
statistical analyses
The statistical analysis was performed using the software GrahPad 
Prism 6.03 (GraphPad Software Inc., CA, USA). The data were 
analyzed using a Kruskal–Wallis test followed by Dunn’s post hoc 
test. p < 0.05 was considered to be significant.
The results were expressed as mean ± SD.
resUlTs
Prl enhances T47D, Zr75-1, and McF-7 
cell Migration
To assess whether PRL influences breast cancer cell motility, we 
pretreated T47D, ZR75-1, and MCF-7 cells with cytosine β-d-
arabinofuranoside hydrochloride, a selective inhibitor of DNA 
synthesis that does not inhibit RNA synthesis, and we performed 
horizontal migration assays as previously described (15, 16). The 
PRL doses of 50 and 100 ng/ml significantly increased mean length 
(micrometer) of migration after 48 h of treatment (Figure 1A) in 
T47D cells (Figure 1A), MCF-7 cells (Figure 1B), and ZR75-1 
cells (Figure  1C). PRL acted through PRLR, as shown by the 
addition of PRLR-siRNAs that results in effective silencing of 
PRLR expression (Figure 1D). In this condition, no increase in 
migration is seen in the presence of PRL (Figures 1A–C). These 
data were similar for all cell lines of this study.
Prl induces actin cytoskeleton 
remodeling
Cell movement is initiated by a global remodeling of the actin 
cytoskeleton. Actin redistribution toward the plasma membrane 
allows formation of membrane ruffles and pseudopodia where 
adhesion to extracellular proteins favors movement. We stained 
with Texas red-linked phalloidin the distribution of actin fibers 
and measured the thickness of plasma membrane area with 
immunofluorescence (Figure  2A), so to quantitatively assess 
actin membrane redistribution. We found that cells treated with 
PRL (at the concentration of 50 and 100 ng/ml) develop a rapid 
remodeling of actin toward the membrane, which corresponds to 
the formation of ruffles and pseudopodia (Figure 2B). Membrane 
FigUre 3 | The figure shows cellular amounts of c-src (a) and p-Tyr530c-src (B) upon administration of different Prl doses (nanogram per milliliter) in 
the presence or absence of anti-hPrlr sirna. The boxes show densitometric analysis of the WB bands adjusted for GAPDH and then normalized to control. 
(c) shows the ratio between c-Src and p-Tyr530c-Src. *p < 0.05 versus control. Experiments were repeated four times.
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actin accumulation during exposure to PRL is also shown by the 
statistically significant increase in thickness of the perimembrane 
area (Figure 2C).
Prl signaling controlling actin 
remodeling
Actin remodeling is tightly controlled. Actin-binding proteins 
such as the Ezrin–Radixin–Moesin (ERM) protein moesin are 
requested to achieve fibrillar actin de-polymerization and reloca-
tion at the cell membrane (18). FAK is later required to form actin/
vinculin-enriched structures called focal adhesion complexes, 
which mediate firm adhesion to the extracellular matrix (ECM) 
(10). Both these controllers are regulated by c-Src, which forms 
multiprotein signaling complexes with a number of membrane 
receptors. The cells exposed to PRL displayed elevated c-Src 
expression and a parallel increase in p-Tyr530 c-Src phosphorylation 
(Figures 3A–B) The Figure 3C shows the ratio between c-Src and 
p-Tyr530 c-Src. In parallel, increased expression of moesin and FAK, 
and enhanced Tyr397FAK and Thr558moesin phosphorylation were 
found in the cells (Figures 4A–H). Modulation of c-Src, moesin, 
and FAK expression and phosphorylation were abolished when 
PRLR was silenced with siRNAs (Figures 3 and 4).
DiscUssiOn
The main result of this work is that PRL increases T47D, ZR75-1, 
and MCF-7 breast cancer cell movement by inducing structural 
changes in the cytoskeleton. This is achieved through signaling 
to the cytoskeletal controllers, moesin and FAK, and turns into a 
remodeling of actin position toward the cell membrane.
Previous evidence indicates that breast cancer cell motility is 
related to the abundance of PRL and PRLR transcripts (19–21), 
therefore suggesting the hypothesis that PRL signaling may have 
a role in this phenomenon. Understanding the means by which 
PRL–PRLR controls the interaction between cancer cells and the 
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extracellular environment thereby influencing breast cancer cell 
motility may have clinical implications (22).
Several levels of evidence suggest that PRL may be directly 
associated with effects on ECM in the context of breast cancer. 
For instance, in a 3D analysis of collagen type 1, it was observed 
that the cells responded with increased ECM’s density after PRL 
stimulation (23). In addition, breast cancer progresses with the 
deposit of fibrillar collagen in the connective tissue near the 
tumor (desmoplasia) (24). In this context, PRL may induce 
reorganization of collagen, increasing the incidence of radially 
oriented fibers and modifying the stiffness of the tissue (25). This 
increased mechanical stiffness of the ECM is known to activate 
FigUre 4 | (a,e) show cellular amounts of PTyr397FAK, FAK, pThr558moesin, and moesin upon administration of different PRL doses (nanogram per milliliter)  
in the presence or absence of anti-hPRLR siRNA. (B,c,F,g) show densitometric analysis of the WB bands adjusted for actin and then normalized to control.  
(D) shows the ratio between FAK and PTyr397FAK. (h) shows the ratio between moesin and pThr558moesin. *p < 0.05 versus control. Experiments were repeated  
four times.
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FAK and Src family kinases (SFK), thereby stimulating cellular 
motility (26). In breast cancer cells, SFKs triggered by PRL may 
generate pro-tumorigenic signals and stimulate cell motility. 
Although JAK2/STAT5 represents the principal physiological 
pathway of PRLR’s action, the signaling to SFKs by this receptor 
could also play a role in breast cancer progression (27).
It is peculiar that modulation of ECM by PRL seems to be 
specifically associated to progression of ER+ breast cancers. In 
this cancer subset, the extent and the type of geometric align-
ment of collagen fibers are predictive of biological aggressiveness 
(28). Approximately 75% of breast cancers express ERs. However, 
ER-targeted therapies fail in about 25% of cases (29). Changes in 
the ECM may thus represent a further area of investigation (23).
Prolactin receptor activation of Src family members has 
previously been studied in other cell types, such as hepatocytes, 
rat lymphocytes (Nb2 and W53), and even in mouse mammary 
epithelial cells (HC11) (10, 30). C-Src is activated through 
direct interaction with cell-membrane receptors, leading to 
auto-phosphorylation and therefore downstream signaling (31). 
Between the many protein kinases controlled by c-Src in breast 
cancer cells, the ERM family member moesin is a key mediator of 
cytoskeletal and cell membrane remodeling. When phosphoryl-
ated, activated moesin depolymerizes and remodels actin toward 
the plasma membrane, inducing the development of a cortical 
actin complex (32). Formation of this membrane actin platform is 
needed to develop transmembrane interactions between the cell’s 
cytoskeleton and proteins of the ECM. A second step that is rel-
evant to achieve cell movement is the formation of focal adhesion 
complexes, or structures enriched in actin and vinculin where 
bridges between the cortical actin complex and the ECM are 
formed through anchoring proteins of the integrin family (33). 
This process is mediated by FAK that promotes the development 
and the turnover of adhesion complexes (34). Later contraction 
of the cytoskeleton allows cell movement. Moesin and FAK are 
overexpressed in breast cancer, and their level of expression is 
related to the metastatic potential (35, 36).
Plasma levels of PRL seem to represent a risk factor for 
breast cancer metastasis (37). Overexpression and functional 
activation of FAK, moesin, and c-SRC in breast cancer cells 
may in part explain this epidemiologic finding. Based on our 
results, it may be hypothesized that some of the effects of PRL 
on breast cancer cell motility may be triggered through recruit-
ment of the small adapter protein, c-Src, and to FAK and moesin 
recruitment, followed by actin rearrangement and enhancement 
of cell motility.
In summary, we here show that T47D, ZR75-1, and MCF-7 
cell motility is enhanced by exposure to PRL. This leads to PRLR-
dependent signaling to c-Src, moesin, and FAK, and to actin 
cytoskeleton remodeling that is related to cell motility. These 
finding highlight new signaling avenues through which PRL may 
influence the biological behavior of breast cancer. These pathways 
may be investigated as new targets for intervention to decrease 
the ability of breast cancer progression.
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